Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management.Zealand Pharma and Roche have entered into a global collaboration and license agreement worth up to $5.3 billion to co-develop and co-commercialize petrelintide, an amylin analog with best-in-class potential, as a foundational therapy [...]

View Entire Post